Form 8-K/A CCC Intelligent Solution For: Apr 27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In connection with his appointment to the position of Interim Chief Financial Officer, the Company and Mr. Christo entered into an Amendment to the Employment Agreement between the Company and Mr. Christo, effective as of the Effective Date (the “Amendment”).
Pursuant to the Amendment, Mr. Christo shall, in addition to continuing to serve as the Senior Vice President, Finance and Chief Accounting Officer of the Company, also serve as the Interim Chief Financial Officer of the Company during the period commencing as of the Effective Date and continuing until the appointment and onboarding of a successor Chief Financial Officer of the Company (such period, as determined in the sole discretion of the Company, the “Transition Period”).
The Amendment provides that (i) during the period beginning on the Effective Date and continuing until three months after a successor Chief Financial Officer is appointed, Mr. Christo’s base salary will be increased to $425,000 per year, and (ii) for fiscal year 2026 and for any portion of any additional fiscal year in which the Transition Period continues, Mr. Christo’s target annual bonus opportunity will be increased to fifty percent (50%) of his then-current base salary. In addition, Mr. Christo will receive a one-time transition cash bonus in an amount between $125,000 and $200,000, with the actual amount to be determined in the sole discretion of the Human Capital and Compensation Committee of the Company based on the length of the Transition Period and the successful onboarding of a successor Chief Financial Officer (the “Transition Bonus”). The Transition Bonus will be payable to Mr. Christo in a lump sum on the first payroll date following the earlier of the expiration of the Transition Period and December 31, 2026. The Transition Bonus shall be forfeited if Mr. Christo’s employment is terminated by the Company for Cause or by Executive without Good Reason (each as defined in the Employment Agreement) prior to the applicable payment date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. |
|
|
|
|
Date: |
May 29, 2026 |
By: |
/s/ Githesh Ramamurthy |
|
|
Name: |
Githesh Ramamurthy |
ATTACHMENTS / EXHIBITS
XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Persistent Strengthens Enterprise AI Engineering Talent Pipeline Through Collaboration with Databricks and Milwaukee School of Engineering
- World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an
- OneStream Introduces Snowflake Connector to Help Finance Scale Trusted AI and Analytics
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share